Spero Therapeutics, Inc.
SPRO
$2.26
$0.2411.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -99.38% | 658.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -99.38% | 658.86% | |||
| Cost of Revenue | 110.66% | -417.35% | |||
| Gross Profit | -102.41% | 3,582.63% | |||
| SG&A Expenses | 13.65% | 3.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.19% | -22.54% | |||
| Operating Income | -124.00% | 528.50% | |||
| Income Before Tax | -122.66% | 530.52% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -122.85% | 526.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -122.85% | 526.98% | |||
| EBIT | -124.00% | 528.50% | |||
| EBITDA | -- | 528.54% | |||
| EPS Basic | -122.34% | 528.89% | |||
| Normalized Basic EPS | -122.17% | 569.67% | |||
| EPS Diluted | -123.46% | 508.31% | |||
| Normalized Diluted EPS | -123.49% | 543.18% | |||
| Average Basic Shares Outstanding | 2.25% | -0.46% | |||
| Average Diluted Shares Outstanding | -3.51% | 5.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||